- Home
- RGTI vs LUNG Comparison
RGTI vs LUNG Comparison
Compare RGTI & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGTI
- LUNG
- Stock Information
- Founded
- RGTI 2013
- LUNG 1995
- Country
- RGTI United States
- LUNG United States
- Employees
- RGTI N/A
- LUNG N/A
- Industry
- RGTI Retail: Computer Software & Peripheral Equipment
- LUNG Industrial Specialties
- Sector
- RGTI Technology
- LUNG Health Care
- Exchange
- RGTI Nasdaq
- LUNG Nasdaq
- Market Cap
- RGTI 285.0M
- LUNG 251.5M
- IPO Year
- RGTI N/A
- LUNG 2020
- Fundamental
- Price
- RGTI $11.40
- LUNG $6.17
- Analyst Decision
- RGTI Strong Buy
- LUNG Buy
- Analyst Count
- RGTI 4
- LUNG 6
- Target Price
- RGTI $3.00
- LUNG $11.92
- AVG Volume (30 Days)
- RGTI 131.4M
- LUNG 214.8K
- Earning Date
- RGTI 11-12-2024
- LUNG 10-30-2024
- Dividend Yield
- RGTI N/A
- LUNG N/A
- EPS Growth
- RGTI N/A
- LUNG N/A
- EPS
- RGTI N/A
- LUNG N/A
- Revenue
- RGTI $11,892,000.00
- LUNG $79,302,000.00
- Revenue This Year
- RGTI N/A
- LUNG $22.26
- Revenue Next Year
- RGTI $47.00
- LUNG $18.72
- P/E Ratio
- RGTI N/A
- LUNG N/A
- Revenue Growth
- RGTI N/A
- LUNG 22.34
- 52 Week Low
- RGTI $0.66
- LUNG $5.46
- 52 Week High
- RGTI $10.68
- LUNG $14.84
- Technical
- Relative Strength Index (RSI)
- RGTI 86.92
- LUNG 44.10
- Support Level
- RGTI $2.88
- LUNG $6.07
- Resistance Level
- RGTI $7.96
- LUNG $6.32
- Average True Range (ATR)
- RGTI 1.51
- LUNG 0.39
- MACD
- RGTI 0.80
- LUNG -0.02
- Stochastic Oscillator
- RGTI 94.39
- LUNG 21.03
About RGTI Rigetti Computing Inc.
Rigetti Computing Inc is engaged in the business of full-stack quantum computing. Its proprietary quantum-classical infrastructure provides ultra-low latency integration with public and private clouds for high-performance practical quantum computing. The company has developed the industry's first multi-chip quantum processor for scalable quantum computing systems. Geographically, it derives a majority of its revenue from the United States.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.